CHICAGO, Sept. 1, 2016
CHICAGO, Sept. 1, 2016 /PRNewswire-USNewswire/ -- The Muscular Dystrophy Association today announced the award of 25 new research, development and research infrastructure grants totaling nearly $7 million and targeted to make an impact on muscular dystrophy, ALS and related life-threatening diseases in its program. The new grants are in addition to 41 grants announced earlier this year and bring MDA's total 2016 commitment to new research aimed at finding treatments and cures across diseases to more than $17 million. The investment reflects MDA's plan to refocus resources in order to double research spending on drug development and clinical trials by the year 2020.
"With this new round of grants, MDA continues to lead the fight against neuromuscular disease by funding top scientists and fueling cutting-edge research around the world aimed at accelerating treatments and cures for MDA families," said MDA's Executive Vice President and Chief Medical & Scientific Officer Valerie A. Cwik, M.D. "Every grant MDA funds has the potential to be the catalyst that will drive the next life-changing medical and scientific advances for every child and adult fighting neuromuscular disease."
For more than six decades, MDA has funded basic, translational and clinical research. The power of MDA's research program lies in its big-picture approach that leverages insights and information resulting from research in one disease area to inform and advance discoveries and breakthroughs in others. This year, MDA has reviewed 443 grant applications and awarded grants to 66 leading scientists conducting innovative research targeted to make an impact across all the diseases in MDA's program.
The latest round of research grants was approved by MDA's Board of Directors after careful deliberations and analysis by MDA's Research Advisory Committee, through which leading clinicians and scientists in volunteer roles oversee the peer-review process. This year, MDA is funding 150 different research projects in 11 countries.
Vital research and services dollars come from generous MDA partners and supporters who organize, and donate to, community fundraising programs such as this summer's Fill The Boot drives led by the International Association of Fire Fighters; retailers who do in-store promotions such as Lowe's, CITGO Petroleum Corp. and Casey's General Stores; and Harley-Davidson Motor Company enthusiasts who raise funds through dealer programs, rides and special events.
"MDA is committed to helping make therapy options available to treat all the diseases under our umbrella as quickly as possible. Thanks to generous partners and donors who champion our work and our cause, we are able to fund the research that will make that day a reality," Cwik added. "We're laser-focused on helping MDA families live longer and grow stronger."
Among the new MDA research grants:
Summer 2016 Grants Materials
MDA has funded more than $1 billion in neuromuscular disease research since 1950, with developments in recent months providing proof points illustrating the strength and determination behind that commitment:
About the Muscular Dystrophy Association
MDA is leading the fight to free individuals — and the families who love them — from the harm of muscular dystrophy, ALS and related muscle-debilitating diseases that take away physical strength, independence and life. We use our collective strength to help kids and adults live longer and grow stronger by finding research breakthroughs across diseases; caring for individuals from day one; and empowering families with services and support in hometowns across America. Learn how you can fund cures, find care and champion the cause at mda.org.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mda-awards-67-million-in-new-research-grants-300321295.html
SOURCE Muscular Dystrophy AssociationPR Newswire
Last updated on: 01/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.